HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ:IPXL) today confirmed that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for generic version of Depakote® (divalproex ER) 500mg Extended-release Tablets. The Company received approval on the 250mg tablets in May 2009. Abbott Laboratories markets Depakote® ER for the treatment of epilepsy and bipolar disorders.
